

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

VOLUNTARY ANNOUNCEMENT

THE SUPPLEMENTARY APPLICATIONS FOR INDICATION EXPANSION OF HANLIKANG (RITUXIMAB INJECTION) APPROVED BY NMPA

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that recently, the supplementary applications of HANLIKANG (rituximab injection) (“**HANLIKANG**”) independently developed by the Company for two additional indications (the “**Additional Indications**”), being the combination with polatuzumab vedotin, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL); and the combination with bendamustine and polatuzumab vedotin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic stem cell transplantation, has been approved by the National Medical Products Administration (the “**NMPA**”).

B. BASIC INFORMATION ON APPROVAL OF THE ADDITIONAL INDICATIONS

Generic Name of the Drug:	Rituximab injection
Trade Name:	HANLIKANG
Dosage:	Injection
Specifications:	100mg/10ml/vial, 500mg/50ml/vial
Registration Classification:	Therapeutic biological products
Drug Manufacturer:	Shanghai Henlius Biopharmaceutical Co., Ltd. * (上海復宏漢霖生物製藥有限公司, a wholly-owned subsidiary of the Company)
Conclusion of Approval:	In accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, upon review, the application for this product complies with relevant requirements for drug registration. The revision of the product insert is hereby approved.

C. ABOUT HANLIKANG

HANLIKANG, a biosimilar of rituximab independently developed by the Company, was approved for commercialization in the Chinese Mainland (excluding Hong Kong, Macao and Taiwan region of China, hereinafter the same) in February 2019. As of the date of this announcement, indications of HANLIKANG approved in the Chinese Mainland are: 1. Non-Hodgkin's Lymphoma (NHL): (1) in combination with chemotherapy for previously untreated patients with CD20-positive stage III-IV follicular NHL; (2) monotherapy maintenance treatment in patients with previously untreated follicular lymphoma who have achieved complete or partial response following rituximab in combination with chemotherapy; (3) relapsed or chemotherapy-refractory follicular lymphoma; (4) in combination with 8 cycles of standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for CD20-positive diffuse large B-cell NHL (DLBCL); (5) in combination with polatuzumab vedotin, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL); (6) in combination with bendamustine and polatuzumab vedotin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic stem cell transplantation; 2. Chronic Lymphocytic Leukemia (CLL): in combination with fludarabine and cyclophosphamide (FC) for the treatment of previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL) patients; 3. Rheumatoid Arthritis (RA): in combination with methotrexate for the treatment of adult patients with moderate to severe active RA who have had an inadequate response to one or more TNF- α inhibitors. Meanwhile, HANLIKANG has also been approved for marketing in Nicaragua and Bolivia.

D. MARKET CONDITION

According to IQVIA CHPA (IQVIA is a global professional information and strategic consulting service provider for the pharmaceutical and healthcare industry), the sales of rituximab injection within the Chinese Mainland amounted to approximately RMB3.465 billion in 2025.

E. IMPACT ON THE COMPANY

The approval of the supplementary application for the new indications of HANLIKANG by the NMPA will further expand the indication spectrum of HANLIKANG and provide more treatment options for adult patients with diffuse large B-cell lymphoma (DLBCL) in China.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 9 April 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.